Search

Your search keyword '"M A C Johnson"' showing total 4 results
Start Over Author "M A C Johnson"
4 results on '"M A C Johnson"'

1. Multi-wavelength Optical and NIR Variability Analysis of the Blazar PKS 0027-426

Author

E Guise, S F Hönig, T Almeyda, K Horne, M Kishimoto, M Aguena, S Allam, F Andrade-Oliveira, J Asorey, M Banerji, E Bertin, B Boulderstone, D Brooks, D L Burke, A Carnero Rosell, D Carollo, M Carrasco Kind, J Carretero, M Costanzi, L N da Costa, T M Davis, J De Vicente, P Doel, S Everett, I Ferrero, B Flaugher, J Frieman, P Gandhi, M Goad, D Gruen, R A Gruendl, J Gschwend, G Gutierrez, S R Hinton, D L Hollowood, K Honscheid, D J James, M A C Johnson, K Kuehn, G F Lewis, C Lidman, M Lima, M A G Maia, U Malik, F Menanteau, R Miquel, R Morgan, R L C Ogando, A Palmese, F Paz-Chinchón, M E S Pereira, A Pieres, A A Plazas Malagón, E Sanchez, V Scarpine, S Serrano, I Sevilla-Noarbe, N Seymour, M Smith, M Soares-Santos, E Suchyta, M E C Swanson, G Tarle, C To, B E Tucker, Univ Southampton, South Carolina State Univ, Univ St Andrews, Kyoto Sangyo Univ, Lab Interinst E Astron LIneA, Fermilab Natl Accelerator Lab, Universidade Estadual Paulista (UNESP), Ctr Invest Energet Medioambientales & Tecnol CIEM, Univ Cambridge, Inst Astrophys Paris, Sorbonne Univ, UCL, Stanford Univ, SLAC Natl Accelerator Lab, Inst Astrofis Canarias, Univ La Laguna, Astrophys Observ Turin, Natl Ctr Supercomp Applicat, Univ Illinois, Barcelona Inst Sci & Technol, Univ Trieste, INAF Osservatorio Astron Trieste, Inst Fundamental Phys Universe, Observ Nacl, Univ Queensland, Santa Cruz Inst Particle Phys, Univ Oslo, Univ Chicago, Univ Leicester, Ludwig Maximilians Univ Munchen, Ohio State Univ, Ctr Astrophys Harvard & Smithsonian, DLR Inst Data Sci, Max Planck Inst Radioastron, Macquarie Univ, Lowell Observ, Univ Sydney, Australian Natl Univ, Universidade de São Paulo (USP), Inst Catalana Recerca & Estudis Avancats, Univ Wisconsin, Univ Michigan, Princeton Univ, Inst Estudis Espacials Catalunya IEEC, CSIC, Curtin Univ, Oak Ridge Natl Lab, Inst Catalan Recerca & Estudis Avancats, University of St Andrews. School of Physics and Astronomy, University of St Andrews. St Andrews Centre for Exoplanet Science, Guise, E, Hönig, S F, Almeyda, T, Horne, K, Kishimoto, M, Aguena, M, Allam, S, Andrade-Oliveira, F, Asorey, J, Banerji, M, Bertin, E, Boulderstone, B, Brooks, D, Burke, D L, Rosell, A Carnero, Carollo, D, Kind, M Carrasco, Carretero, J, Costanzi, M, da Costa, L N, Davis, T M, De Vicente, J, Doel, P, Everett, S, Ferrero, I, Flaugher, B, Frieman, J, Gandhi, P, Goad, M, Gruen, D, Gruendl, R A, Gschwend, J, Gutierrez, G, Hinton, S R, Hollowood, D L, Honscheid, K, James, D J, Johnson, M A C, Kuehn, K, Lewis, G F, Lidman, C, Lima, M, Maia, M A G, Malik, U, Menanteau, F, Miquel, R, Morgan, R, Ogando, R L C, Palmese, A, Paz-Chinchón, F, Pereira, M E S, Pieres, A, Malagón, A A Plaza, Sanchez, E, Scarpine, V, Serrano, S, Sevilla-Noarbe, I, Seymour, N, Smith, M, Soares-Santos, M, Suchyta, E, Swanson, M E C, Tarle, G, To, C, and Tucker, B E

Subjects
quasars individual PKS 0027-426, Astrophysics::High Energy Astrophysical Phenomena, galaxies active, jets [galaxies], FOS: Physical sciences, galaxies jets, Astrophysics::Cosmology and Extragalactic Astrophysics, Astrophysics, 01 natural sciences, Astrophysic, 0103 physical sciences, QB Astronomy, Astrophysics::Solar and Stellar Astrophysics, Astrophysics of Galaxie, 010303 astronomy & astrophysics, High Energy Astrophysical Phenomena, QC, Astrophysics::Galaxy Astrophysics, QB, High Energy Astrophysical Phenomena (astro-ph.HE), Astrophysics of Galaxies, 010308 nuclear & particles physics, galaxies jet, Astronomy and Astrophysics, DAS, Astrophysics - Astrophysics of Galaxies, individual: PKS 0027-426 [quasars], QC Physics, 13. Climate action, Space and Planetary Science, Astrophysics of Galaxies (astro-ph.GA), active [galaxies], Astrophysics - High Energy Astrophysical Phenomena
Abstract

We present multi-wavelength spectral and temporal variability analysis of PKS 0027-426 using optical griz observations from DES (Dark Energy Survey) between 2013-2018 and VOILETTE (VEILS Optical Light curves of Extragalactic TransienT Events) between 2018-2019 and near infrared (NIR) JKs observations from VEILS (VISTAExtragalactic Infrared Legacy Survey) between 2017-2019. Multiple methods of cross-correlation of each combination of light curve provides measurements of possible lags between optical-optical, optical-NIR, and NIR-NIR emission, for each observation season and for the entire observational period. Inter-band time lag measurements consistently suggest either simultaneous emission or delays between emission regions on timescales smaller than the cadences of observations. The colour-magnitude relation between each combination of filters was also studied to determine the spectral behaviour of PKS 0027-426. Our results demonstrate complex colour behaviour that changes between bluer when brighter (BWB), stable when brighter (SWB) and redder when brighter (RWB) trends over different timescales and using different combinations of optical filters. Additional analysis of the optical spectra is performed to provide further understanding of this complex spectral behaviour., Accepted for publication in MNRAS. 33 pages, 28 figures, 11 tables

Published
2021

2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, P.G. Oriol, A. Beksac, M. Liberati, A.M. Galli, M. Schjesvold, F. Lindsay, J. Weisel, K. White, D. Facon, T. San Miguel, J. Sunami, K. O'Gorman, P. Sonneveld, P. Robak, P. Semochkin, S. Schey, S. Yu, X. Doerr, T. Bensmaine, A. Biyukov, T. Peluso, T. Zaki, M. Anderson, K. Dimopoulos, M. Abildgaard, N. Adler, H. Altuntas, F. Akay, O.M. Amin, B. Anagnostopoulos, A. Anderson, L. Anttila, P. Araujo, C. Arce-Lara, C. Aydin, Y. Basu, S. Battini, R. Beeker, T. Benboubker, L. Ben-Yehuda, D. Bladé, J. Blau, I.W. Boccia, R. Burke, L. Byeff, P. Cascavilla, N. Cavo, M. Chantry, A. Charles, Y. Chaudhry, A. Corso, A. Coyne, M. De Arriba, F. Delimpasi, S. Desjardins, P. Dhakal, B. Di Bartolomeo, P. Di Raimondo, F. Dürig, J. Engelhardt, M. Escoffre-Barbe, M. Esteves, G. Flogegard, M. Gabrail, N. Gamberi, B. Garrison, M. Gay, J. Gisslinger, H. Goldschmidt, H. Goncalves, C. Gressot, L. Grosicki, S. Hanna, W. Hayden, P. Henriques Bernardo, M.M. Hermann, R. Holden, V. Honkalehto, K. Huben, M. Huffman, J. Hunter, H. Hus, M. Jagasia, M. Jagganath, S. Janakiram, M. Jaiyesimi, I. Jenner, M. João, C. Johnson, P. Jurcyszyn, A. Kalayoğlu Beşişik, S. Kambhampati, S. Kanate, A. Karadoğan, I. Khojasteh, A. Kirkel, D. Komarnicki, M. Krauth, M.-T. Kuriakose, P. Larocca, A. Lauri, B. Leleu, X. Lucio, P. Luppi, M. Mangiacavalli, S. Mariette, C. Matsue, K. Mellqvist, U.-H. Mendeleeva, L. Meshad, M. Miller, C. Mohrbacher, A. Moreau, P. Morelli, A.M. Müldür, E. Naassan, A. Nahi, H. Nair, R. O'Dwyer, M. Öngören Aydin, S. Openshaw, T. O'Rourke, T. Osswald, M. Overton, L. Pati, A. Pavic, M. Pegourie, B. Pehlivan, M. Pierola, A.A. Plesner, T. Pluta, A. Rabin, N. Ramasamy, K. Rambaldi, A. Rodriguez, P. Röllig, C. Rosenblatt, J. Rosenbluth, J. Salomo, M. Samoylova, O. Sastre Moral, J. Sati, H. Selleri, C. Shafeek, S. Shinagawa, A. Sleckman, B. Smith, C. Sonmez, M. Stone, C. Streetly, M. Suzuki, K. Taetle, R. Tafuri, A. Takezako, N. Teke, H.Ü. Vapaatalo, M. Vassilopoulos, G. Verma, A. Vidito, S. Viterbo, L. Vural, F. Wang, X.S. Yağci, M. Yee, A. OPTIMISMM trial investigators

Subjects
hemic and lymphatic diseases
Abstract

Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods: We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged ≥18 years)with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0–2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1)to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of β2 microglobulin at screening. Bortezomib (1·3 mg/m2)was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years])was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1–14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings: Between Jan 7, 2013, and May 15, 2017, 559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15·9 months (IQR 9·9–21·7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11·20 months [95% CI 9·66–13·73]vs 7·10 months [5·88–8·48]; hazard ratio 0·61, 95% CI 0·49–0·77; p

Published
2019

3. Febuxostat and atrial fibrillation

Author

Masanari Kuwabara, Richard J. Johnson, Claudio Borghi, and Kuwabara M, Borghi C, Johnson RJ

Subjects
medicine.medical_specialty, Gout, business.industry, Allopurinol, MEDLINE, Atrial fibrillation, Febuxostat, atrial fibrillation, medicine.disease, Medicare, United States, Gout Suppressants, Text mining, Febuxostat, Internal medicine, Atrial Fibrillation, medicine, Cardiology, Humans, Cardiology and Cardiovascular Medicine, business, medicine.drug, Aged
Abstract

Recently there has been concern that febuxostat may be associated with increased cardiovascular risk than allopurinol,1 leading to a black-box warning by the Federal Drug Administration. Consistent with these concerns, Singh and Cleveland2 have recently reported that febuxostat also increased the risk for atrial fibrillation (AF) in a population-based cohort study of individuals greater than 65 years old, using Medicare data. The study evaluated individuals initiating allopurinol or febuxostat therapy and compared the incidence of AF with the prior year before starting treatment, controlling for comorbidities using the Charlson-Romero index and propensity matched Cox regression analysis.

Published
2020

4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesu, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thoma, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletio, OPTIMISMM trial investigator, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., and Hematology

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Adolescent, Population, Dexamethasone, Bortezomib, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Survival rate, Lenalidomide, Multiple myeloma, Aged, Salvage Therapy, education.field_of_study, business.industry, Pomalidomide, bortezomib, dexamethasone, Middle Aged, Pomalidomide, medicine.disease, Prognosis, Thalidomide, Survival Rate, Regimen, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Multiple Myeloma, 030215 immunology, medicine.drug, Follow-Up Studies
Abstract

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged >= 18 years) with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of beta(2) microglobulin at screening. Bortezomib (1.3 mg/m(2)) was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1,4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1-14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings Between Jan 7, 2013, and May 15,2017,559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15.9 months (IQR 9.9-21.7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11.20 months [95% CI 9.66-13-73] vs 7.10 months [5.88-8-48]; hazard ratio 0.61, 95% CI 0.49-0-77; p

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results